Why the study?
Are there specific features of ambulatory blood pressure monitoring profiles in hypertensive patients with resistant left ventricular hypertrophy compared to those with LVH regression?
Are there specific features of ambulatory blood pressure monitoring profiles in hypertensive patients with resistant left ventricular hypertrophy compared to those with LVH regression?
There are no specific features of the ABPM profile in patients with resistant LVH, but pulse pressure changes correlate with LVMI changes, suggesting its role as a risk factor for LVH.
Answers are grounded in this paper and cite their sources.
No ABPM profile distinguishes resistant LVH; pulse pressure changes were associated with LVMI, hypothesis-generating for its role in progression.
The objective of the study was assessment of ABPM values changes during one-year antihypertensive therapy in essentially hypertensive (EH) patients with and without regression of left ventricular hypertrophy (LVH). Standard ABPM was performed after 4 weeks of placebo and in one year of antihypertensive treatment in 40 (16 men, 24 women) EH patients with echocardiographically verified LVH (LV mass index [LVMI] >120 g/sq.m in men and >100 g/sq.m in women). Group 1 included 17 patients with resistant LVH (LVMI decrease <10% comparing to baseline), Group 2 included 23 patients with regression of LVH (LVMI decrease >10% comparing to baseline). At baseline Group 2 had higher values of day- and nighttime pulse pressure (PP) than Group 1 (respectively 58,0±1,4 vs 53,0±1,5 mmHg, 52,4±1,7 vs 46,0±1,7 mmHg, p<0,05) and higher daytime systolic BP variability (16,2±0,2 vs 14,8±0,5 mmHg, p<0,05). In Group 2 SBP/DBP decrease was 5,4%/ 5,6% during 24h, 5,3%/6,7% during daytime, 7,4%/7,6%- during nighttime. In Group 1 respectively 5,5%/6,6%, 6,7%/8,4%, 6,9%/6,3%. Decrease of daytime PP was 2,4% (p>0,05 to baseline) in Group 1 and 10,2% (p<0,05 to baseline and to Group 1) in Group 2. Decrease of nighttime PP was respectively 8,7% (p>0,05 to baseline) and 10,7% (p<0,05 to baseline). No significant difference in ABPM values achieved at the end of treatment between groups was revealed. Significant decrease of variability of daytime systolic BP (from 16,2±0,2 to 14,5±0,2 mmHg, p<0,05) and nighttime PP (from 13,8±0,4 to 12,4±0,2 mmHg, p<0,05) was observed in Group 2. In Group 1 BP variability changes were not significant. Diurnal index (DI) increased in Group 2 (systolic from 9,6±1,1% to 13,6±1,2%, p<0,05, and diastolic from 12,4±1,0% to 14,2±1,5%, p>0,05). In Group 1 DI changed respectively from 12,8±1,6% to 13,0±1,2% and from 15,3±2,0% to 13,7±1,2% (p>0,05 in both cases). Baseline LVMI correlated (Spearmen analysis) to 24-h (r=0,54) and nighttime (r=0,62) systolic BP, daytime (r=0,66) and nighttime (r=0,70) PP. In Group 2 LVMI changes significantly correlated to changes of daytime and nighttime PP (r=0,56 and r=0,62). No significant correlation between changes of LVMI and ABPM values was revealed in Group 1. The data obtained suggested no specific features of ABPM profile in patients with resistant LVH. Correlations between PP and LVMI changes suggest important role of PP as a risk factor either for LVH per se and resistant LVH.
No takes yet. Share an insight, caveat, or question.
Zhanna Kobalava (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: